Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

Abstract Background A randomized, controlled, phase 3b study (ALPINE) evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) using a 1-day initiation regimen in patients hospitalized for an acute exacerbation of schizophrenia. Paliperidone palmitate (PP) was used as an...

Full description

Bibliographic Details
Main Authors: Henry A. Nasrallah, Peter J. Weiden, David P. Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxton
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Psychiatry
Subjects:
Antipsychotic drugs
Intramuscular injections
Quality of life
Dependency burden
Paliperidone palmitate
Online Access:https://doi.org/10.1186/s12888-021-03420-x

Similar Items

Similar Items